STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$1.80 USD
+0.25 (16.13%)
Updated Aug 15, 2024 03:59 PM ET
After-Market: $1.80 0.00 (0.00%) 7:42 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LAB 1.80 +0.25(16.13%)
Will LAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LAB
Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates
5 Medical Info Systems Stock to Buy for a Stable Portfolio
LAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LAB
$1.7M Bet On Standard BioTools? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Standard BioTools to Participate in Upcoming Investor Conferences
MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday
Maintaining a Buy Rating for Standard BioTools: Overcoming Short-Term Challenges with Long-Term Growth Potential
What You Missed On Wall Street This Morning